Journal of the American Society of Nephrology : JASN · 2026
Platelet Cyclophilin D Drives Cholesterol Crystal Embolism-Related Acute Kidney Injury and Kidney Infarction.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Cong, Yang Luying, Ku John, Boor Peter, Zu Juan, Han Chao, Kuang Meisi, Fei Ye, Liu Fuyao, Long Hao, Li Qiubo, Chang Liang, Yang Huan, Chu Xiang, Aghakishi Heydar, Klinkhammer Barbara Mara, Gudermann Thomas, Mammadova-Bach Elmina, Anders Hans-Joachim
Аннотация
KEY POINTS: Cholesterol crystal embolism causes arterial thrombosis, ischemic necrosis, and organ dysfunction. Genetic depletion of cyclophilin D reduced cholesterol crystal embolism-induced thromboinflammation and protected organ function. Pharmacological inhibition of cyclophilin D and transmembrane protein 16F limited cholesterol crystal embolism-induced thrombosis and improved kidney function.
BACKGROUND: Cholesterol crystal embolism is a severe consequence of advanced atherosclerosis, where intra-arterial cholesterol crystal can trigger organ injury and failure. Cyclophilin D (CypD), a key regulator of the mitochondrial permeability transition pore, promotes procoagulant platelet formation and necrosis. We hypothesized that CypD-dependent procoagulant platelet formation enhances cholesterol crystal embolism-induced thromboinflammatory responses and kidney injury.
METHODS: We used CypD-deficient mice and pharmacologic inhibitors (cyclosporine A to block CypD and niflumic acid to inhibit transmembrane protein 16F as a downstream effector of CypD) to determine the role of CypD during cholesterol crystal-induced kidney thromboinflammation and injury.
RESULTS: Cholesterol crystal injection into the renal artery caused infarction, thromboinflammation, and AKI in wild-type mice, whereas CypD-deficient mice were protected. Global or platelet-specific CypD deletion preserved GFR, reduced infarct size, and attenuated tubular damage. Pharmacological inhibition of CypD with cyclosporin A conferred similar protection. Inhibition of transmembrane protein 16F-dependent phosphatidylserine exposure with niflumic acid also reduced CypD-mediated procoagulant activity and limited kidney injury.
CONCLUSIONS: Our findings identified platelet CypD and downstream phosphatidylserine exposure as key mediators of cholesterol crystal-induced thromboinflammation.
BACKGROUND: Cholesterol crystal embolism is a severe consequence of advanced atherosclerosis, where intra-arterial cholesterol crystal can trigger organ injury and failure. Cyclophilin D (CypD), a key regulator of the mitochondrial permeability transition pore, promotes procoagulant platelet formation and necrosis. We hypothesized that CypD-dependent procoagulant platelet formation enhances cholesterol crystal embolism-induced thromboinflammatory responses and kidney injury.
METHODS: We used CypD-deficient mice and pharmacologic inhibitors (cyclosporine A to block CypD and niflumic acid to inhibit transmembrane protein 16F as a downstream effector of CypD) to determine the role of CypD during cholesterol crystal-induced kidney thromboinflammation and injury.
RESULTS: Cholesterol crystal injection into the renal artery caused infarction, thromboinflammation, and AKI in wild-type mice, whereas CypD-deficient mice were protected. Global or platelet-specific CypD deletion preserved GFR, reduced infarct size, and attenuated tubular damage. Pharmacological inhibition of CypD with cyclosporin A conferred similar protection. Inhibition of transmembrane protein 16F-dependent phosphatidylserine exposure with niflumic acid also reduced CypD-mediated procoagulant activity and limited kidney injury.
CONCLUSIONS: Our findings identified platelet CypD and downstream phosphatidylserine exposure as key mediators of cholesterol crystal-induced thromboinflammation.